Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies

Next Previous
X
Search
Trial Profile

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LBL-007 (Primary) ; Tislelizumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Nasopharyngeal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nanjing Leads Biolabs

    • Most Recent Events

    • 24 Oct 2024 Planned End Date changed from 30 Jun 2025 to 30 Dec 2025.
    • 24 Oct 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
    • 04 Jun 2024 Results (As of January 10, 2024, n=21) assessing safety and efficacy of LBL-007 in combination with tislelizumab with or without chemotherapy in advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top